A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111)

BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase I and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tum...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pediatr Blood Cancer
Main Authors: Geller, James I., Perentesis, John P., Liu, Xiaowei, Minard, Charles G., Kudgus, Rachel A., Reid, Joel M., Fox, Elizabeth, Blaney, Susan M., Weigel, Brenda J.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5657151/
https://ncbi.nlm.nih.gov/pubmed/28449393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26565
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki